Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Basilea Pharmaceutica AG's Board Proposes Martin Nicklasson To Succeed Chairman Werner Henrich
Basilea Pharmaceutica AG announced that its Board of Directors proposes Dr. Martin Nicklasson as designated non-executive Chairman of the Board of Directors to succeed Werner Henrich whose term will end at the upcoming AGM. Mr. Henrich will not stand for re-election as he will reach the statutory age limit for board members in 2013. Dr. Martin Nicklasson proposed for election to the Basilea Board of Directors.
Latest Developments for Basilea Pharmaceutica AG
- Basilea Pharmaceutica AG submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
- Basilea Pharmaceutica AG announces isavuconazole received QIDP designation from U.S. FDA
- Basilea Pharmaceutica AG Isavuconazole receives orphan drug designations in Europe
- Basilea Pharmaceutica AG's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study
Latest Key Developments in Biotechnology
- Share this
- Digg this